Granted Patent
B2
US 12,084,449 · App. 17/575,371 · Granted Sep 10, 2024
Imidazotriazines and imidazopyrimidines as kinase inhibitors
Inventors:
Jincong Zhuo (Boothwyn, PA); Meizhong Xu (Hockessin, DE); Chunhong He (Boothwyn, PA); Colin Zhang (Ambler, PA); Ding-Quan Qian (Newark, DE); David M. Burns (Philadelphia, PA); Yun-Long Li (Chadds Ford, PA); Brian Metcalf (Moraga, CA); Wenqing Yao (Kennett Square, PA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Claims (1)
1. A method of treating lung cancer in a patient in need thereof comprising administering to said patient a therapeutically effective amount of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, or a pharmaceutically acceptable salt thereof.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 22, 2022
From: ZHUO, JINCONG; XU, MEIZHONG; HE, CHUNHONG; ZHANG, COLIN; QIAN, DING-QUAN; BURNS, DAVID M.; LI, YUN-LONG; METCALF, BRIAN; YAO, WENQING
To: INCYTE CORPORATION
Reel/Frame 059672/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 22, 2022
From: INCYTE CORPORATION
To: INCYTE CORPORATION; INCYTE HOLDINGS CORPORATION
Reel/Frame 059672/0354 →
Continuity (10)
Provisional Application
60957236
· Aug 22, 2007
Provisional Application
60861459
· Nov 29, 2006
Provisional Application
60860840
· Nov 22, 2006